Novel Drug for Relapsing-Remitting MS: New Phase 2 Data Novel Drug for Relapsing-Remitting MS: New Phase 2 Data

The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news